Archive

ASCO Daily News Archive

The ASCO Daily News is the official news source for the ASCO Annual Meeting, providing expert perspectives on controversial topics and session highlights. Articles include physician-authored “Expert Editorials” on current clinical issues in oncology, interviews with Meeting attendees, and recaps of key sessions and presentations. Content is current as of the Meeting date and may not reflect the most recent data.


July 23, 2018

CAR T-cell immunotherapy earned the title “Advance of the Year” in the ASCO Clinical Cancer Advances 2018 annual report.

Read more

July 23, 2018

The 2018 ASCO Annual Meeting featured the results of multiple large phase III trials aimed at establishing whether the use of PD-1/PD-L1 checkpoint inhibitors can enhance outcomes in metastatic non–small cell lung cancer (NSCLC).

Read more

July 23, 2018

Many notable abstracts were accepted as posters, poster discussions, or oral presentations for the 2018 Annual Meeting.

Read more

July 23, 2018

Ongoing advancements in radiation oncology were among the highlights of the 2018 ASCO Annual Meeting. Approximately 80% of all patients with cancer receive radiation therapy as part of their treatment, Steven E. Finkelstein, MD, FACRO, of the Advanced Urology Institute, said.

Read more

July 23, 2018

In the following interview, the ASCO Daily News spoke with Stephen Leong, MD, of the University of Colorado School of Medicine, about immunotherapy’s progress in the field of gastrointestinal (GI) cancers and what he learned from abstracts presented during the 2018 ASCO Annual Meeting.

Read more

July 23, 2018

Several sessions during the 2018 ASCO Annual Meeting dealt with issues about survivorship and patient-reported outcomes. ASCO Daily News interviewed Don S. Dizon, MD, FACP, FASCO, of Lifespan Cancer Institute, about his key takeaways.

Read more

July 23, 2018

Lung cancer is a notoriously difficult condition to treat, with mortality rates exceeding those from the next four deadliest cancers—breast, colon, prostate, and pancreatic—combined.

Read more

July 23, 2018

In the following interview, internationally renowned cancer researcher and medical oncologist Derek Raghavan, MD, PhD, FACP, FRACP, FASCO, of Carolinas HealthCare System’s Levine Cancer Institute, details his views on the field of immunotherapy in bladder cancer.

Read more

July 23, 2018

The ASCO Daily News spoke recently with Edward S. Kim, MD, of the Carolinas Healthcare System Levine Cancer Institute, about key data presented during the 2018 ASCO Annual Meeting regarding drug activity across tumor types.

Read more

July 23, 2018

In his work, Travis Osterman, DO, MS, an instructor in biomedical informatics at Vanderbilt University Medical Center, applies medical informatics to cancer treatment and research.

Read more
July 23, 2018

As mortality rates for breast cancer have improved in high-income countries over the last several decades, there is increasing focus on patient quality of life and avoiding long-term morbidities.

Read more

June 14, 2018

Inclusion of biologic factors in breast cancer staging in the American Joint Committee on Cancer (AJCC) eighth edition marks a significant change that highlights the importance of underlying tumor biology for staging.

Read more

June 14, 2018

Amidst the flood of immunotherapy trials being conducted in non–small cell lung cancer (NSCLC), interim data from two pivotal phase III trials of atezolizumab are beginning to inform if and how the anti–PD-L1 inhibitor may be used in the first-line setting.

Read more

June 14, 2018

Many types of cancer treatments, including new targeted agents and immunotherapies, can cause cardiac toxicities.

Read more

June 14, 2018

The anti–PD-1 antibody pembrolizumab previously demonstrated superior overall survival (OS) in patients with advanced melanoma compared with ipilimumab in the phase III, multicenter randomized KEYNOTE-006 trial (NCT01866319).

Read more

June 14, 2018

Adding bevacizumab to the tyrosine kinase inhibitor (TKI) erlotinib significantly extended progression free-survival (PFS) in patients with late-stage or recurrent chemotherapy-naive EGFR-mutated non–small cell lung cancer (NSCLC) with good tolerability.

Read more

June 14, 2018

Dacomitinib is a second-generation EGFR tyrosine kinase inhibitor (TKI). This agent was compared with gefitinib in the phase III open-label ARCHER1050 trial in patients with advanced non–small cell lung cancer (NSCLC) with EGFR-activating mutations.

Read more
June 14, 2018

Combination therapy with the oral BCL-2 inhibitor venetoclax plus a hypomethylating agent demonstrated a tolerable safety profile in elderly patients with untreated acute myeloid leukemia (AML) who were ineligible for standard induction chemotherapy.

Read more

June 14, 2018

In a small population of patients with advanced castration-resistant prostate cancer (CRPC), the anti–PD-1 inhibitor pembrolizumab had some anticancer activity, according to the results of KEYNOTE-199 (Abstract 5007) presented on June 4.

Read more

June 14, 2018

Black men are more likely than white men to die as a result of prostate cancer in the United States.

Read more